Clinical Trial

Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

Study acronym: MSC-DKD-001
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is to evaluate the efficacy and safety of umbilical cord-derived mesenchymal stromal cells (Amimestrocel ) in study subjects with progressive diabetic kidney disease (DKD), to investigate whether Amimestrocel can improve renal function or proteinuria of DKD patients.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-05-15 -> 2026-08-15 2026-07-15
Trial Details
NCT Number NCT06969807
Lead Sponsor Chinese PLA General Hospital
Conditions Diabetic Kidney Disease (DKD)
Enrollment 120 participants
Start Date 2025-06-09
Primary Completion 2026-08-15 (estimated)
Study Completion 2028-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-14